Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
Authors
Keywords
-
Journal
CLINICAL PHARMACOKINETICS
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-03-08
DOI
10.1007/s40262-018-0644-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
- (2017) Fernanda Musa et al. GYNECOLOGIC ONCOLOGY
- Systems Chronotherapeutics
- (2017) Annabelle Ballesta et al. PHARMACOLOGICAL REVIEWS
- Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: A systematic review
- (2017) Olaguoke Akinwande et al. SURGICAL ONCOLOGY-OXFORD
- Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice
- (2016) Sander A Huisman et al. BRITISH JOURNAL OF PHARMACOLOGY
- Lack of pharmacokinetic drug–drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors
- (2016) Ding Wang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer
- (2016) Giuseppe Toffoli et al. CLINICAL CANCER RESEARCH
- Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study
- (2016) Francis Lévi et al. CLINICAL PHARMACOKINETICS
- ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia
- (2016) M Li et al. PHARMACOGENOMICS JOURNAL
- Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses
- (2016) J M Campbell et al. PHARMACOGENOMICS JOURNAL
- Pathological complete response following neoadjuvant radiotherapy and intraperitoneal perfusion chemotherapy for recurrent colon carcinoma: A case report and literature review
- (2016) XINYU BIAN et al. Oncology Letters
- Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis
- (2015) Xue-Qin Yang et al. BMC CANCER
- OATP1B1 and tumour OATP1B3 modulate exposure, toxicity and survival after irinotecan-based chemotherapy
- (2015) W A Teft et al. BRITISH JOURNAL OF CANCER
- Fasting protects against the side effects of irinotecan but preserves its anti-tumor effect in Apc15lox mutant mice
- (2015) Sander A Huisman et al. CELL CYCLE
- Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study
- (2015) Michal Mego et al. COMPLEMENTARY THERAPIES IN MEDICINE
- UGT1A1genotype and irinotecan therapy: general review and implementation in routine practice
- (2015) Marie-Christine Etienne-Grimaldi et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver
- (2015) Rabih Said et al. INVESTIGATIONAL NEW DRUGS
- Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure
- (2015) Alexander K. Berg et al. JOURNAL OF CLINICAL PHARMACOLOGY
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- (2015) Chiara Cremolini et al. LANCET ONCOLOGY
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling
- (2015) S. Dulong et al. MOLECULAR CANCER THERAPEUTICS
- Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma
- (2015) K. B. Peters et al. ONCOLOGIST
- ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients
- (2015) Sylvia Chen et al. Pharmacogenetics and Genomics
- Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study
- (2015) D J Crona et al. PHARMACOGENOMICS JOURNAL
- Effect of Cellular Location of Human Carboxylesterase 2 on CPT-11 Hydrolysis and Anticancer Activity
- (2015) Yuan-Ting Hsieh et al. PLoS One
- Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis
- (2014) Gabriel Glockzin et al. BMC CANCER
- MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
- (2014) Rajesh V. Lalla et al. CANCER
- Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
- (2014) Fei-fei Han et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Irinotecan and temozolomide brain distribution: a focus on ABCB1
- (2014) Lauriane Goldwirt et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians
- (2014) Lei Cheng et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Old Drug New Use--Amoxapine and Its Metabolites as Potent Bacterial -Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity
- (2014) R. Kong et al. CLINICAL CANCER RESEARCH
- Herb–Drug Interactions in Oncology
- (2014) A K L Goey et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662
- (2014) M H M Diekstra et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Advances in pharmacotherapy of small cell lung cancer
- (2014) Gregory P Kalemkerian EXPERT OPINION ON PHARMACOTHERAPY
- A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer
- (2014) Jaafar Bennouna et al. INVESTIGATIONAL NEW DRUGS
- Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to theUGT1A1Genotype of Patients With Cancer
- (2014) Federico Innocenti et al. JOURNAL OF CLINICAL ONCOLOGY
- Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective
- (2014) Roelof W F van Leeuwen et al. LANCET ONCOLOGY
- The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis
- (2014) M M Dias et al. PHARMACOGENOMICS JOURNAL
- A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan
- (2014) Bryan K. Kee et al. SUPPORTIVE CARE IN CANCER
- The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis
- (2013) Yi-Jing Chen et al. BIOMARKERS
- S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
- (2013) S Y Kim et al. BRITISH JOURNAL OF CANCER
- Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract
- (2013) Filippo Caraci et al. CURRENT DRUG METABOLISM
- A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)
- (2013) Gary Middleton et al. EUROPEAN JOURNAL OF CANCER
- PharmGKB summary
- (2013) Julia M. Barbarino et al. Pharmacogenetics and Genomics
- Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
- (2013) X Liu et al. PHARMACOGENOMICS JOURNAL
- The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance?
- (2013) S. Casey Laizure et al. PHARMACOTHERAPY
- Polymorphisms of the UDP-Glucuronosyl Transferase 1A Genes Are Associated with Adverse Events in Cancer Patients Receiving Irinotecan-Based Chemotherapy
- (2013) Kazuyuki Inoue et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
- (2012) A Roy et al. BRITISH JOURNAL OF CANCER
- Irinotecan Loaded in Eluting Beads: Preclinical Assessment in a Rabbit VX2 Liver Tumor Model
- (2012) Pramod P. Rao et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results of Pharmacokinetics and Phase I Trial
- (2012) Robert C. G. Martin et al. JOURNAL OF GASTROINTESTINAL SURGERY
- A Cell-Delivered and Cell-Activated SN38-Dextran Prodrug Increases Survival in a Murine Disseminated Pancreatic Cancer Model
- (2012) Matthew T. Basel et al. Small
- UGT1A1predicts outcome in colorectal cancer treated with irinotecan and fluorouracil
- (2012) Yan Wang WORLD JOURNAL OF GASTROENTEROLOGY
- Closed Abdomen Hyperthermic Intraperitoneal Chemotherapy with Irinotecan and Mitomycin C: a Phase I Study
- (2011) Eddy Cotte et al. ANNALS OF SURGICAL ONCOLOGY
- Comparative Analysis of Esterase Activities of Human, Mouse, and Rat Blood
- (2011) E. V. Rudakova et al. BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
- The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients
- (2011) Jacqueline Ramírez et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
- (2011) L. Elens et al. CLINICAL CHEMISTRY
- Pharmacogenetics: From Bench to Byte— An Update of Guidelines
- (2011) J J Swen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: A prospective cross-over drug–drug interaction study
- (2011) Jessica M. van der Bol et al. EUROPEAN JOURNAL OF CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circadian Timing in Cancer Treatments
- (2010) Francis Lévi et al. Annual Review of Pharmacology and Toxicology
- A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
- (2010) E Boven et al. BRITISH JOURNAL OF CANCER
- Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
- (2010) C Garufi et al. BRITISH JOURNAL OF CANCER
- Effects of methimazole on the elimination of irinotecan
- (2010) Jessica M. van der Bol et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding
- (2010) Moon Ki Choi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A CYP3A4 Phenotype-Based Dosing Algorithm for Individualized Treatment of Irinotecan
- (2010) J. M. van der Bol et al. CLINICAL CANCER RESEARCH
- Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk
- (2010) Z.-Y. Hu et al. CLINICAL CANCER RESEARCH
- Dose-dependent association between UGT1A1∗28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis
- (2010) Zhe-Yi Hu et al. EUROPEAN JOURNAL OF CANCER
- Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration
- (2010) Byung-Jin Ahn et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine
- (2010) Laura W. Goff et al. INVESTIGATIONAL NEW DRUGS
- Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741
- (2010) Howard L. McLeod et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis
- (2010) G. Masi et al. JNCI-Journal of the National Cancer Institute
- Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma
- (2010) Maryam B. Lustberg et al. Journal of Thoracic Oncology
- Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
- (2010) B Glimelius et al. PHARMACOGENOMICS JOURNAL
- Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
- (2010) D Wang et al. PHARMACOGENOMICS JOURNAL
- Therapeutic Targeting of Melanoma Cells Using Neural Stem Cells Expressing Carboxylesterase, a CPT-11 Activating Enzyme
- (2010) Margarita Gutova et al. Current Stem Cell Research & Therapy
- A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction
- (2009) M. Moehler et al. ANNALS OF ONCOLOGY
- A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
- (2009) M. Ychou et al. ANNALS OF ONCOLOGY
- Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy
- (2009) Yosuke Horita et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors
- (2009) Crystal S. Denlinger et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
- (2009) GENETICS IN MEDICINE
- Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803
- (2009) Monica M. Bertagnolli et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan
- (2009) Erika Cecchin et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
- (2009) Federico Innocenti et al. JOURNAL OF CLINICAL ONCOLOGY
- Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer
- (2009) Giuseppe Toffoli et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- UGT1A1*28genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan
- (2009) Roberta Ferraldeschi et al. PHARMACOGENOMICS
- Effects of Oral Administration of S-1 on the Pharmacokinetics of SN-38, Irinotecan Active Metabolite, in Patients With Advanced Colorectal Cancer
- (2009) Koji Yokoo et al. THERAPEUTIC DRUG MONITORING
- A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer
- (2008) A. Santoro et al. ANNALS OF ONCOLOGY
- Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
- (2008) M. Dank et al. ANNALS OF ONCOLOGY
- Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck
- (2008) Jill Gilbert et al. CANCER
- A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma
- (2008) Joanna M. Brell et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies
- (2008) Y. Xu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma
- (2008) Islam R. Younis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Food–drug interaction of (−)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38
- (2008) Lie-Chwen Lin et al. CHEMICO-BIOLOGICAL INTERACTIONS
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
- (2008) Alberto F. Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer
- (2008) Ji-Youn Han et al. LUNG CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started